CCR2 and neoplasm: This indicated complete tumor rejection in the majority of the UBC-GFP cohort, which was contrary to our expectations given that 100% (9 of 9) of tumors took in another tolerized strain: Cx3cr1-GFP;CCR2-RFP mice, with final tumor burden similar to that of NOD-SCID mice (p = 0.78) (4).